Shoreline Biosciences, a genome editing company, agreed to acquire the iNK cell franchise and gene editing technologies of Editas Medicine, a biotechnology company. Financial terms were not disclosed. “The acquisition of our allogeneic iNK franchise by Shoreline is highly aligned with our strategic portfolio reprioritization, as it allows us to sharpen our efforts on advancing current clinical stage trials and focus our resources on in vivo fit-for-purpose therapeutic construction and development. Shoreline is a leader in developing next generation iNK and macrophage cell therapies, and we believe they are the right company to move these assets toward clinical applications," Gilmore O’Neill, Editas Medicine President and CEO.